Sharon Townson
Vermogen: 1 M $ op 31-05-2026
Vermogen: 1 M $ op 31-05-2026
Dr. Sharon Townson is a Chief Scientific Officer at Monte Rosa Therapeutics, Inc. Dr. Townson was previously employed as an Executive Director & Head-Platform Biology by Kymera Therapeutics, Inc. and a Scientific Director-Physical Biochemistry by Warp Drive Bio, Inc. She received her undergraduate degree from the University of Salford and a doctorate degree from the University of Manchester Institute of Science & Technology.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 23-06-2026 | 67.845 ( 0,08% ) | 1 M $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| MONTE ROSA THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-01-2021 |
| Bedrijven | Functie | Einde |
|---|---|---|
| KYMERA THERAPEUTICS, INC. | Directeur/Bestuurslid | 01-06-2020 |
Warp Drive Bio, Inc.
Warp Drive Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Focuses on proprietary genomic technology to discover drugs of natural origin | Corporate Officer/Principal | 01-12-2018 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 5 |
|---|---|
University of Salford
University of Salford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Manchester Institute of Science & Technology
University of Manchester Institute of Science & Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Warp Drive Bio, Inc.
Warp Drive Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Focuses on proprietary genomic technology to discover drugs of natural origin | Commercial Services |
Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops immunology medicines for health problems | Health Technology |
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops molecular glue degrader medicines for oncology, autoimmune and inflammatory diseases | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau